Network pharmacology-based approach of novel traditional Chinese medicine formula for treatment of acute skin inflammation in silico

被引:30
作者
Tang, Hsin-Chieh [1 ]
Huang, Hung-Jin [1 ]
Lee, Cheng-Chun [2 ]
Chen, Calvin Yu Chian [1 ,3 ,4 ]
机构
[1] China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan
[2] China Med Univ, Coll Med, Sch Med, Taichung 40402, Taiwan
[3] Asia Univ, Dept Bioinformat & Med Engn, Taichung 41354, Taiwan
[4] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Guangzhou 510275, Guangdong, Peoples R China
关键词
Matrix metalloproteinase-9 (MMP-9); Acne vulgaris; Quantitative structure-activity relationship (QSAR); Protein-protein interaction (PPI); Traditional Chinese medicine (TCM); MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; MATRIX-METALLOPROTEINASE-9; MMP-9; DESIGN; ACNE; DOCKING; BINDING; CANCER; CELLS;
D O I
10.1016/j.compbiolchem.2017.08.013
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Matrix metalloproteinase-9 (MMP-9) appears to play an important role in acute skin inflammation. Subantimicrobial dose of tetracycline has been demonstrated to inhibit the activity of MMP-9 protein. However, long-term use tetracycline will induce side effect. The catalytic site of MMP-9 is located at zinc binding amino acids, His401, His405 and His411. We attempted to search novel medicine formula as MMP-9 inhibitors from traditional Chinese medicine (TCM) database by using in silico studies. We utilized high-throughput virtual screening to find which natural compounds could bind to the zinc binding site. The quantitative structure-activity relationship (QSAR) models, which constructed by scaffold of MMP-9 inhibitors and its activities, were employed to predict the bio-activity of the natural compounds for MMP-9. The results showed that Celacinnine, Lobelanidine and Celallocinnine were qualified to interact with zinc-binding site and displayed well predictive activity. We found that celallocinnine was the best TCM compound for zinc binging sites of MMP-9 because the stable interactions were observed under dynamic condition. In addition, Celacinnine and Lobelanidine could interact with MMP-9 related protein that identified by drug-target interaction network analysis. Thus, we suggested the herbs Hypericum patulum, Sedum acre, and Tripterygium wilfordii that containing Celallocinnine, Celacinnine and Lobelanidine might be a novel medicine formula to avoid the side effect of tetracycline and increase the efficacy of treatment. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:70 / 81
页数:12
相关论文
共 49 条
[1]   Structure-based design, synthesis, molecular docking, and biological activities of 2-(3-benzoylphenyl) propanoic acid derivatives as dual mechanism drugs [J].
Ahmed, Musa A. ;
Azam, Faizul ;
Rghigh, Abir M. ;
Gbaj, Abdul ;
Zetrini, Abdulmottaleb E. .
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2012, 4 (01) :43-50
[2]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[3]   ASTACINS, SERRALYSINS, SNAKE-VENOM AND MATRIX METALLOPROTEINASES EXHIBIT IDENTICAL ZINC-BINDING ENVIRONMENTS (HEXXHXXGXXH AND MET-TURN) AND TOPOLOGIES AND SHOULD BE GROUPED INTO A COMMON FAMILY, THE METZINCINS [J].
BODE, W ;
GOMISRUTH, FX ;
STOCKLER, W .
FEBS LETTERS, 1993, 331 (1-2) :134-140
[4]   The contributions of the tissue inhibitor of metalloproteinase-1 genotypes to triple negative breast cancer risk [J].
Chang, Wen-Shin ;
Liu, Liang-Chih ;
Hsiao, Chieh-Lun ;
Su, Chen-Hsien ;
Wang, Hwei-Chung ;
Ji, Hong-Xue ;
Tsai, Chia-Wen ;
Maa, Ming-Chei ;
Bau, Da-Tian .
BIOMEDICINE-TAIWAN, 2016, 6 (01) :23-28
[7]  
CHEN SY, 2016, BIOMEDICINE TAIWAN, V6, P1, DOI [DOI 10.7603/s40681-016-0007-3, DOI 10.7603/S40681-016-0007-3]
[8]   Variability in docking success rates due to dataset preparation [J].
Corbeil, Christopher R. ;
Williams, Christopher I. ;
Labute, Paul .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2012, 26 (06) :775-786
[9]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[10]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174